Abstract
The aim of the study was to evaluate the association between tumor clinicopathological characteristics and circulating tumor cells (CTCs) in breast cancer. We searched PubMed, MEDLINE, BioMed, and EMbase databases for studies that assessed the association between tumor clinicopathological characteristics and CTCs in breast cancer. Studies obtained from search strategy were screened using pre-specified criteria, and necessary data were retrieved for meta-analysis. Fourteen studies with 2,336 patients were eligible for combined analysis. Presence of CTCs in peripheral blood (PB) was significantly associated with tumor size [OR 0.68, 95 % confidence interval (CI) (0.54, 0.87), n = 10, P = 0.002], tumor grade [OR 0.71, 95 % CI (0.55, 0.91), n = 8, P = 0.006], ER status [OR 0.72, 95 % CI (0.57, 0.91), n = 9, P = 0.007], and PR status [OR 0.78, 95 % CI (0.61, 0.98), n = 9, P = 0.04]. However, as to correlation between nodal status and CTCs presence in PB, no statistically significant difference was found [OR 0.83, 95 % CI (0.67, 1.03), n = 12, P = 0.10]. The CTCs’ presence in PB is correlated with tumor size, tumor grade, ER, and PR.
Similar content being viewed by others
Abbreviations
- CTCs:
-
Circulating tumor cells
- ER:
-
Estrogen receptor
- hMAM:
-
Human mammaglobin
- LSC:
-
Laser scanning cytometry
- OS:
-
Overall survival
- PFS:
-
Progression-free survival
- PR:
-
Progesterone receptor
- PB:
-
Peripheral blood
References
Wulfing P, Borchard J, Buerger H, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006;12:1715–20.
Pierga JY, Bonneton C, Vincent-Salomon A, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res. 2004;10:1392–400.
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.
Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4(6):448–56.
Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–21.
Ring AE, Zabaglo L, Ormerod MG, et al. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer. 2005;92(5):906–12.
Pantel K, Riethdorf S. Pathology: are circulating tumor cells predictive of overall survival? Nat Rev Clin Oncol. 2009;6(4):190–1.
Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8:329–40.
Criscitiello C, Sotiriou C, Ignatiadis M. Circulating tumor cells and emerging blood biomarkers in Breast Cancer. Curr Opin Oncol. 2010;22:552–8.
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.
Lang JE, Mosalpuria K, Cristofanilli M, et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. 2009;113:501–7.
Tao M, Ma D, Li Y, Zhou C, et al. Clinical significance of circulating tumor cells in breast cancer patients. Breast Cancer Res Treat. 2011;129:247–54.
Biggers B, Knox S, Grant M, et al. Circulating tumor cells in patients undergoing surgery for primary breast cancer: preliminary results of a pilot study. Ann Surg Oncol. 2009;16:969–71.
Ferro P, Franceschin MC, Bacigalupo B, et al. Detection of circulating tumour cells in breast cancer patients using human mammaglobin RT-PCR:association with clinical prognostic factors. Anticancer Res. 2010;30:2377–82.
Yan Y, Cheng JP, Di LJ, Song GH, Ren J. Detection and clinical value of epithelial cellular adhension molecule (EpCAM) mRNA positive circulating tumor cells in metastatic breast cancer. Beijing Da Xue Xue Bao. 2012;44(2):275–80.
Molloy TJ, Bosma AJ, Baumbusch LO, et al. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res. 2011;13(3):R61.
Nadal R, Fernandez A, Sanchez-Rovira P, et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 2012;14(3):R71.
Molloy TJ, Devriese LA, Helgason HH, Bosma AJ, Hauptmann M, Voest EE, Schellens JHM, van’t Veer LJ. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer. 2011;104:1913–9.
Heo CK, Hwang HM, Ruem AH, et al. Identification of a mimotope for circulating anti-cytokeratin 8/18 antibody and its usage for the diagnosis of breast cancer. Int J Oncol. 2013;42:65–74.
Hwang SB, Bae JW, Lee HY, Kim HY. Circulating tumor cells detected by RT-PCR for CK-20 before surgery indicate worse prognostic impact in triple-negative and HER2 subtype breast cancer. J Breast Cancer. 2012;15(1):34–42.
Giuliano M, Giordano A, Jackson S, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011;13(3):R67.
Xenidis N, Vlachonikolis I, Mavroudis D, et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol. 2003;14:849–55.
Xenidis N, Ignatiadis M, Apostolaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 2009;27:2177–84.
Ignatiadis M, Rothe F, Chaboteaux C, et al. HER2-positive circulating tumor cells in breast cancer. PLoS One. 2011;6(1):e15624.
Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012;18:5701–10.
Janni W, Vogl FD, Wiedswang G, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse: a European pooled analysis. Clin Cancer Res. 2011;17:2967–76.
Zhang L, Riethdorf S, Wu G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012;18(20):5701–10.
Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.
Cristofanilli M, Hayes D, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;3:1420–30.
Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8):793–802.
Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–21.
Sandri MT, Zorzino L, Cassatella MC, Bassi F, Luini A, et al. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol. 2010;17:1539–45.
Ring A, Smith IE, Dowsett M. Circulating tumour cells in breast cancer. Lancet Oncol. 2004;5:79–88.
Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry A. 2007;71:154–62.
Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Yi Liao and Shu-Yi Wang have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Liao, Y., Wang, SY., Meng, XY. et al. Circulating tumor cells in breast cancer and its association with tumor clinicopathological characteristics: a meta-analysis. Med Oncol 31, 343 (2014). https://doi.org/10.1007/s12032-014-0343-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-014-0343-7